Debiopharm licenses new antitumour candidate
This article was originally published in Scrip
Executive Summary
Debiopharm of Switzerland has signed an exclusive licence agreement for the development and commercialisation of a small molecule in early preclinical development from the Moffitt Cancer Center, a non-profit US organisation.